Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher. “Biotech was a coiled spring following several quarters of underperformance,” Dr. Terry Smith, ...
A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...
Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results